Bio-Techne (MIL:1TECH) Current Deferred Revenue: €33 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MIL:1TECH Bio-Techne Corp MIL:1TECH
58 GF Score
Price €62.06
GF Value €62.64
Valuation Modestly Undervalued
! 8 Warning Signs
View Full Analysis

What is Bio-Techne Current Deferred Revenue?

Bio-Techne MIL:1TECH 58 Current Deferred Revenue is €33 Mil as of Mar. 2026. GuruFocus rates MIL:1TECH with a GF Score™ of 58/100 and a GF Value™ of €62.64 (Modestly Undervalued). The stock has 8 warning signs investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

Bio-Techne's current deferred revenue for the quarter that ended in Mar. 2026 was €33 Mil.

Bio-Techne Current Deferred Revenue Related Terms

Bio-Techne Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for Bio-Techne's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bio-Techne Current Deferred Revenue Chart

Bio-Techne Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 15.77 22.14 21.29 25.95 28.24

Bio-Techne Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Current Deferred Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.85 28.24 25.94 26.50 33.25
MIL:1TECH
58GF Score
Bio-Techne Corp MIL:1TECH
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of €33 Mil mean?
Bio-Techne (MIL:1TECH) has a Current Deferred Revenue of €33 Mil as of Mar. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bio-Techne and its competitors.
Is Bio-Techne's Current Deferred Revenue too high?
Bio-Techne's current Current Deferred Revenue is €33 Mil. Overall, Bio-Techne has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bio-Techne's Current Deferred Revenue compare to CYTK and SMMT?
Bio-Techne's Current Deferred Revenue of €33 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on Bio-Techne and its competitors. Bio-Techne's current Current Deferred Revenue is €33 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio-Techne stock overvalued right now?
Based on GuruFocus' analysis, Bio-Techne (MIL:1TECH) is currently considered Modestly Undervalued. The stock's GF Value™ is €62.64, compared to a current price of €62.06 — trading 0.9% below its estimated fair value. The current Current Deferred Revenue is €33 Mil. Bio-Techne's overall GF Score™ is 58/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For Bio-Techne (MIL:1TECH), the current Current Deferred Revenue is €33 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bio-Techne (MIL:1TECH) Overvalued in 2026?

Based on GuruFocus' analysis, Bio-Techne stock appears to be undervalued. The current stock price of €62.06 is trading 0.9% below its estimated GF Value™ of €62.64. GuruFocus considers Bio-Techne to be Modestly Undervalued.

Key valuation signals for MIL:1TECH:

  • Current Deferred Revenue: €33 Mil
  • GF Value™: €62.64 vs. price of €62.06 (0.9% below fair value)
  • GF Score™: 58/100 with 8 warning signs

No single metric tells the full story. See the MIL:1TECH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bio-Techne Business Description

Address 614 McKinley Place N.E., Minneapolis, MN, USA, 55413
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (about 75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
58GF Score

Get the complete analysis for MIL:1TECH

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€62.06
Price
€62.64
GF Value